

At Home Program - CIIC Patient Referral Form

Admissions Phone: 855-937-7273 Admissions Fax: 844-878-6917

Patient Demograpl	hics Informati	on						
Patient Name						SSN#	DOB	
Patient Address						•	I	
Primary Phone Ce			Cellular Ph	one	Work Phone			
CIIC At Home Program Provider Name						Provider Contact Number		
Emergency Contact Name & Relationship						Emergency Contact Number		
Additional Docume	entation Need	ed						
- Patient facesheet with demographics - CBC w/ diff, BMP & CMP (within 1 year) - Vital signs including blood pressure								
- History and physical			- For imm	une deficiency, detailed	l infection history, IgG and IgA le	vels, and vaccine responses		
Patient Clinical Inf								
Gender	Height (in.)		Weight (lbs)		Allergies (food/drug)			
Statement of Medic	cal Necessity /	Primary Di	agnosis	5				
ICD10:				Description of diagnosis:				
Subcutaneous Imn	nunoglobulin -	Medication	ı Inforn	nation/Prescript	ion and Orders			
Medication:	Dose:				Directions:			ty / Refills
□ Cutaquig 16.5% □ Cuvitru 20% □ Gammagard 10% □ Gammaked 10%	Loading:	oading: grams subcutaneo over days (Infuse subcutaneously p	Dispense: 1 months supply, refill x12mo. unless otherwise noted □ Other		
□ Gamunex-C 10% □ Hizentra 20% PFS □ HyQvia 10% □ Xembify 20%					*Pharmacy to provide all necessary supplies to complete infusion per manufacturer guidelines and provider order.			
Premedication(s) □ Give premedication(s) 30 minutes prior to infusion (s) Acetaminophen: □ 325mg tab: 3 diphenhydrAMINE: □ 25mg cap: 25				g-650mg PO	ed) □ 160mg/5mL oral susp: mg PO □ 12.5mg/5mL oral liquid: mg PO		_	cy #QS, refills PRN otherwise noted
	*If subsequer	nt treatment o	only Da	ate of last infusion _	Date next	infusion due		
Injectable Biologic	s - Medication			cription and Ord			_	
Medication:	Dosage Form:			Dose and Directions:		ty / Refills		
□ Fasenra (benralizumab)		□ 10mg/0.5mL prefilled syringe □ 30mg/mL prefilled syringe			Inject mg subcutaneously every week(s)		Dispense: 1 month supply Refill: x12 months unless otherwise noted	
□ Nucala (mepolizumab)		□ 40mg/0.4mL prefilled syringe □ 100mg/mL prefilled syringe			Inject mg subcutaneously every week(s)			
□ Xolair (omalizumab)		□ 75mg/0.5mL prefilled syringe □ 150mg/mL prefilled syringe □ 300mg/2mL prefilled syringe			Inject mg subcutaneously every week(s)		□ Othe	r
			.91mL pr	efilled syringe	Inject mg sub every week(s)			
	*Pharmacy to	provide all ne	ecessary :	supplies to complet	e infusion per manufacture	er guidelines and provid	ler order.	
	*If subsequen	it treatment o	nly Da	te of last injection _	Date nex	t injection due		
Prescriber Informa	ation							
Ordering Provider Name NPI#				NPI#		Office/Clinic Contact		
Clinic Name						Clinic Phone		
Clinic Address						Clinic Fax		
Provider Signature Required - Substitution Permitted Date					Provider Signature Required - Dis	L pense as Written		Date
				•	i e			